

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/SE05/000495

International filing date: 05 April 2005 (05.04.2005)

Document type: Certified copy of priority document

Document details: Country/Office: SE  
Number: 0400925-4  
Filing date: 06 April 2004 (06.04.2004)

Date of receipt at the International Bureau: 19 April 2005 (19.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**PRV**PATENT- OCH REGISTRERINGSVERKET  
Patentavdelningen**Intyg  
Certificate**

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.


(71) Sökande                      AstraZeneca AB, Södertälje SE  
Applicant (s)

(21) Patentansökningsnummer    0400925-4  
Patent application number

(86) Ingivningsdatum                      2004-04-06  
Date of filing

Stockholm, 2005-04-12

För Patent- och registreringsverket  
For the Patent- and Registration Office



Avgift  
Fee

CHEMICAL COMPOUNDS

The present invention concerns piperidine derivatives having pharmaceutical activity, to processes for preparing such derivatives, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives as active therapeutic agents.

Pharmaceutically active piperidine derivatives are disclosed in WO99/38514, WO99/04794 and WO00/35877.

Histamine is a basic amine, 2-(4-imidazolyl)-ethylamine, and is formed from histidine by histidine decarboxylase. It is found in most tissues of the body, but is present in high concentrations in the lung, skin and in the gastrointestinal tract. At the cellular level inflammatory cells such as mast cells and basophils store large amounts of histamine. It is recognised that the degranulation of mast cells and basophils and the subsequent release of histamine is a fundamental mechanism responsible for the clinical manifestation of an allergic process. Histamine produces its actions by an effect on specific histamine G-protein coupled receptors, which are of three main types, H1, H2 and H3. Histamine H1 antagonists comprise the largest class of medications used in the treatment of patients with allergic disorders, especially rhinitis and urticaria. H1 antagonists are useful in controlling the allergic response by for example blocking the action of histamine on post-capillary venule smooth muscle, resulting in decreased vascular permeability, exudation and oedema. The antagonists also produce blockade of the actions of histamine on the H1 receptors on c-type nociceptive nerve fibres, resulting in decreased itching and sneezing.

Chemokines are chemotactic cytokines that are released by a wide variety of cells to attract macrophages, T cells, eosinophils, basophils and neutrophils to sites of inflammation and also play a rôle in the maturation of cells of the immune system. Chemokines play an important rôle in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C, or  $\alpha$ ) and Cys-Cys (C-C, or  $\beta$ ) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.


The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).

The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1 $\alpha$  and 1 $\beta$  (MIP-1 $\alpha$  and MIP-1 $\beta$ ).

Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3 and CXCR4. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.

Viral infections are known to cause lung inflammation. It has been shown experimentally that the common cold increases mucosal output of eotaxin in the airways. Instillation of eotaxin into the nose can mimic some of the signs and symptoms of a common cold. (See, Greiff L *et al* Allergy (1999) 54(11) 1204-8 [Experimental common cold increase mucosal output of eotaxin in atopic individuals] and Kawaguchi M *et al* Int. Arch. Allergy Immunol. (2000) 122 S1 44 [Expression of eotaxin by normal airway epithelial cells after virus A infection].)

The present invention provides a compound of formula (I):



wherein:

one of A, B, D, E and G is CXYCO<sub>2</sub>R<sup>5</sup>, another is CH or N and the others are CR<sup>2</sup>, CR<sup>3</sup> and CR<sup>4</sup>;

Q is hydrogen or hydroxy;

W is CH<sub>2</sub>, O, NH or N(C<sub>1-4</sub> alkyl);

X is O or a bond;

Y is CR<sup>10</sup>R<sup>11</sup>, CR<sup>10</sup>R<sup>11</sup>CR<sup>12</sup>R<sup>13</sup>, CR<sup>10</sup>R<sup>11</sup>CR<sup>12</sup>R<sup>13</sup>CR<sup>14</sup>R<sup>15</sup>;

- $R^1$  is phenyl optionally substituted by halogen, cyano,  $C_{1-4}$  alkyl,  $C_{1-4}$  haloalkyl,  $C_{1-4}$  alkoxy or  $C_{1-4}$  haloalkoxy;
- $R^2$ ,  $R^3$  and  $R^4$  are, independently, hydrogen, halogen, cyano, nitro, hydroxy,  $NR^6R^7$ ,  $C_{1-6}$  alkyl (optionally substituted with halogen),  $C_{1-6}$  alkoxy (optionally substituted with
- 5 halogen),  $S(O)_p(C_{1-6} \text{ alkyl})$ ,  $S(O)_qCF_3$  or  $S(O)_2NR^8R^9$ ;
- $R^5$  is hydrogen,  $C_{1-6}$  alkyl or benzyl;
- $p$  and  $q$  are, independently, 0, 1 or 2;
- $R^6$ ,  $R^7$ ,  $R^8$  and  $R^9$  are, independently, hydrogen,  $C_{1-6}$  alkyl (optionally substituted by halogen, hydroxy or  $C_{3-6}$  cycloalkyl),  $CH_2(C_{2-5} \text{ alkenyl})$ , phenyl (itself optionally
- 10 substituted by halogen, hydroxy, nitro,  $NH_2$ ,  $NH(C_{1-4} \text{ alkyl})$ ,  $N(C_{1-4} \text{ alkyl})_2$  (and these alkyl groups may join to form a ring as described for  $R^6$  and  $R^7$  below),  $S(O)_2(C_{1-4} \text{ alkyl})$ ,  $S(O)_2NH_2$ ,  $S(O)_2NH(C_{1-4} \text{ alkyl})$ ,  $S(O)_2N(C_{1-4} \text{ alkyl})_2$  (and these alkyl groups may join to form a ring as described for  $R^6$  and  $R^7$  below), cyano,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy,  $C(O)NH_2$ ,  $C(O)NH(C_{1-4} \text{ alkyl})$ ,  $C(O)N(C_{1-4} \text{ alkyl})_2$  (and these alkyl groups may join to form a ring as
- 15 described for  $R^6$  and  $R^7$  below),  $CO_2H$ ,  $CO_2(C_{1-4} \text{ alkyl})$ ,  $NHC(O)(C_{1-4} \text{ alkyl})$ ,  $NHS(O)_2(C_{1-4} \text{ alkyl})$ ,  $C(O)(C_{1-4} \text{ alkyl})$ ,  $CF_3$  or  $OCF_3$ ) or heterocyclyl (itself optionally substituted by halogen, hydroxy, nitro,  $NH_2$ ,  $NH(C_{1-4} \text{ alkyl})$ ,  $N(C_{1-4} \text{ alkyl})_2$  (and these alkyl groups may join to form a ring as described for  $R^6$  and  $R^7$  below),  $S(O)_2(C_{1-4} \text{ alkyl})$ ,  $S(O)_2NH_2$ ,  $S(O)_2NH(C_{1-4} \text{ alkyl})$ ,  $S(O)_2N(C_{1-4} \text{ alkyl})_2$  (and these alkyl groups may join to form a ring
- 20 as described for  $R^6$  and  $R^7$  below), cyano,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy,  $C(O)NH_2$ ,  $C(O)NH(C_{1-4} \text{ alkyl})$ ,  $C(O)N(C_{1-4} \text{ alkyl})_2$  (and these alkyl groups may join to form a ring as described for  $R^6$  and  $R^7$  below),  $CO_2H$ ,  $CO_2(C_{1-4} \text{ alkyl})$ ,  $NHC(O)(C_{1-4} \text{ alkyl})$ ,  $NHS(O)_2(C_{1-4} \text{ alkyl})$ ,  $C(O)(C_{1-4} \text{ alkyl})$ ,  $CF_3$  or  $OCF_3$ );
- alternatively  $NR^6R^7$  or  $NR^8R^9$  may, independently, form a 4-7 membered heterocyclic ring,
- 25 azetidine, pyrrolidine, piperidine, azepine, morpholine or piperazine, the latter optionally substituted by  $C_{1-4}$  alkyl on the distal nitrogen;
- $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$  and  $R^{15}$  are, independently, hydrogen or  $C_{1-4}$  alkyl; or  $R^{10}$  and  $R^{11}$ , and the carbon to which they are both attached, together form a  $C_{3-6}$  cycloalkyl ring, for  $C_{4-6}$  cycloalkyl rings said ring optionally having a ring carbon, but not the ring carbon to
- 30 which  $R^{10}$  and  $R^{11}$  are both attached, replaced by O,  $S(O)$  or  $S(O)_2$ ;
- or an N-oxide thereof; or a pharmaceutically acceptable salt thereof; or a solvate thereof.

Certain compounds of the present invention can exist in different isomeric forms (such as enantiomers, diastereomers, geometric isomers or tautomers). The present invention covers all such isomers and mixtures thereof in all proportions.

Suitable salts include acid addition salts such as a hydrochloride, dihydrochloride, hydrobromide, phosphate, sulfate, acetate, diacetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulfonate or *p*-toluenesulfonate.

The compounds of the invention may exist as solvates (such as hydrates) and the present invention covers all such solvates.

Halogen includes fluorine, chlorine, bromine and iodine. Halogen is, for example, fluorine or chlorine.

Alkyl groups and moieties are straight or branched chain and comprise, for example, 1 to 6 (such as 1 to 4) carbon atoms. Examples of alkyl groups are methyl, ethyl, *n*-propyl, *iso*-propyl or *tert*-butyl.

Haloalkyl groups and moieties comprise an alkyl part, as defined above, and one or more (for example 1 to 6) of the same or different halogen atoms. Haloalkyl is, for example, CH<sub>2</sub>F, CHF<sub>2</sub> or CF<sub>3</sub>.

Alkenyl groups comprise, for example, 2 to 6 (such as 2 to 4) carbon atoms. Examples of alkenyl groups are vinyl or allyl.

In one embodiment cycloalkyl groups comprise from 3 to 6 carbon atoms and are monocyclic. Cycloalkyl is, for example, cyclopropyl, cyclopentyl or cyclohexyl.

Heterocyclyl is an aromatic or non-aromatic 5 or 6 membered ring, optionally fused to one or more other rings, comprising at least one heteroatom selected from the group comprising nitrogen, oxygen and sulfur; or an N-oxide thereof, or an S-oxide or S-dioxide thereof. Heterocyclyl is, for example, furyl, thienyl (also known as thiophenyl), pyrrolyl, 2,5-dihydropyrrolyl, thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, piperidinyl, morpholinyl, pyridinyl, dihydropyridinyl (for example in a 6-oxo-1,6-dihydro-pyridinyl moiety), pyrimidinyl, indolyl, 2,3-dihydroindolyl, benzo[b]furyl (also known as benzfuryl), benz[b]thienyl (also known as benzthienyl or benzthiophenyl), 2,3-dihydrobenz[b]thienyl (for example in a 1-dioxo-2,3-dihydrobenz[b]thienyl moiety), indazolyl, benzimidazolyl, benztriazolyl, benzoxazolyl, benzthiazolyl (for example in a 1H-benzthiazol-2-one-yl moiety), 2,3-dihydrobenzthiazolyl (for example in a 2,3-dihydrobenzthiazol-2-one-yl moiety), 1,2,3-benzothiadiazolyl, an imidazopyridinyl (such as imidazo[1,2a]pyridinyl), thieno[3,2-b]pyridin-6-yl, 1,2,3-benzoxadiazolyl, benzo[1,2,3]thiadiazolyl, 2,1,3-

benzothiadiazolyl, benzofurazan (also known as 2,1,3-benzoxadiazolyl), quinoxaliny, dihydro-1-benzopyryliumyl (for example in a coumariny or a chromonyl moiety), 3,4-dihydro-1H-2,1-benzothiazinyl (for example in a 2-dioxo-3,4-dihydro-1H-2,1-benzothiazinyl moiety), a pyrazolopyridine (for example 1H-pyrazolo[3,4-b]pyridinyl), a purine (for example in a 3,7-dihydro-purin-2,6-dione-8-yl moiety), quinolinyl, isoquinolinyl, dihydroisoquinolinyl (for example in a 2H-isoquinolin-1-one-yl moiety), a naphthyridinyl (for example [1,6]naphthyridinyl or [1,8]naphthyridinyl), a dihydro[1,8]naphthyridinyl (for example in a 1H-[1,8]naphthyridin-4-one-yl moiety), a benzothiazinyl, a dihydrobenzothiazinyl (for example in a 4H-benzo[1,4]thiazin-3-one-yl moiety), benzo[d]imidazo[2,1-b]thiazol-2-yl or dibenzothiophenyl (also known as dibenzothienyl); or an N-oxide thereof, or an S-oxide or S-dioxide thereof.

An N-oxide of a compound of formula (I) is, for example, a 1-oxy-[1,4']bipiperidinyl-1'-yl compound.

In one particular aspect the invention provides a compound of formula (I) wherein W is O.

In another aspect  $R^1$  is phenyl optionally substituted (for example independently mono- or di-substituted) with halogen (for example chlorine or fluorine),  $C_{1-4}$  alkyl (for example methyl) or  $C_{1-4}$  alkoxy (for example methoxy).

In a further aspect  $R^1$  is phenyl optionally substituted (for example with one, two or three of the same or different) with fluorine, chlorine, cyano,  $C_{1-4}$  alkyl (for example methyl) or  $C_{1-4}$  alkoxy (for example methoxy). In a still further aspect  $R^1$  is phenyl substituted by one, two or three (for example two or three) substituents independently selected from: fluorine, chlorine, cyano and methyl. For example  $R^1$  is 3,4-dichlorophenyl, 2,4-dichloro-3-methylphenyl, 3,4-dichloro-2-methylphenyl, 2,4-dichlorophenyl, 4-chloro-2-methylphenyl, 2-chloro-4-fluorophenyl, 4-fluorophenyl or 3-chloro-4-cyanophenyl.

In a still further aspect of the invention Q is hydrogen.

In another aspect of the invention  $R^5$  is hydrogen.

In yet another aspect of the present invention  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$  and  $R^{15}$  are, independently, H or  $C_{1-4}$  alkyl (for example methyl).

In a further aspect of the invention XY is  $CH_2$ ,  $CH_2CH_2$ ,  $OCH_2$ ,  $OC(CH_3)_2$  or  $OCHCH_3$ .

In a still further aspect of the invention when XY is  $CR^{10}R^{11}$ ,  $CR^{10}R^{11}CR^{12}R^{13}$  or  $CR^{10}R^{11}CR^{12}R^{13}CR^{14}R^{15}$  then A, B or D is  $CXYCO_2R^5$ .

In another aspect of the invention when XY is  $\text{OCR}^{10}\text{R}^{11}$ ,  $\text{OCR}^{10}\text{R}^{11}\text{CR}^{12}\text{R}^{13}$  or  $\text{OCR}^{10}\text{R}^{11}\text{CR}^{12}\text{R}^{13}\text{CR}^{14}\text{R}^{15}$  then A, B or D is  $\text{CXYCO}_2\text{R}^5$ .

In yet another aspect of the invention  $\text{R}^2$ ,  $\text{R}^3$  and  $\text{R}^4$ , are, independently, hydrogen, halogen, cyano,  $\text{C}_{1-4}$  alkyl (such as methyl or ethyl),  $\text{C}_{1-4}$  alkoxy (such as methoxy or ethoxy),  $\text{CF}_3$ ,  $\text{OCF}_3$ ,  $\text{S(O)}_2(\text{C}_{1-4} \text{ alkyl})$  (such as  $\text{S(O)}_2\text{CH}_3$ ) or  $\text{S(O)}_2\text{NH}_2$  {for example  $\text{R}^2$ ,  $\text{R}^3$  and  $\text{R}^4$ , are, independently, hydrogen, halogen, cyano, nitro,  $\text{C}_{1-4}$  alkyl (such as methoxy or ethoxy)  $\text{C}_{1-4}$  alkoxy (such as methoxy or ethoxy)  $\text{CF}_3$  or  $\text{OCF}_3$ }.

In a further aspect of the invention one of  $\text{R}^2$ ,  $\text{R}^3$  and  $\text{R}^4$  is hydrogen or  $\text{C}_{1-4}$  alkoxy (such as methoxy).


In a still further aspect the present invention provides a compound of formula (I) wherein: Q is hydrogen; W is O; E is CH; one of A, B, D and G is  $\text{CXYCO}_2\text{H}$ , and the others are  $\text{CR}^2$ ,  $\text{CR}^3$  and  $\text{CR}^4$  (wherein  $\text{R}^2$ ,  $\text{R}^3$  and  $\text{R}^4$  are, independently, hydrogen or  $\text{C}_{1-4}$  alkoxy (such as methoxy);  $\text{R}^1$  is phenyl substituted by halogen (for example by one or two chlorine atoms); and XY is  $\text{CH}_2$ ,  $\text{CH}_2\text{CH}_2$ ,  $\text{OCH}_2$ ,  $\text{OC}(\text{CH}_3)_2$  or  $\text{OCHCH}_3$ .

The compounds of the present invention can be prepared as described below.

A compound of formula (I) wherein  $\text{R}^5$  is H can be prepared from a compound of formula (I) wherein  $\text{R}^5$  is alkyl by hydrolysis, for example with a suitable hydroxide (such as an alkali metal hydroxide, for example lithium hydroxide) in a suitable solvent (for example a  $\text{C}_{1-6}$  aliphatic alcohol such as methanol) typically at room temperature (for example  $10-30^\circ\text{C}$ ).

A compound of formula (I) where  $\text{R}^5$  is alkyl can be formed from a compound of formula (I) where  $\text{R}^5$  is H by procedures (such as esterification) which are well-known in the art.


A compound of formula (I) wherein  $\text{R}^5$  is H can be formed from a compound of formula (II):



wherein one of A, B, D, E, or G represents  $\text{CXYCN}$  by hydrolysis of the nitrile under conditions well-known in the art.




A compound of formula (I) or (II) can be prepared by reacting a compound of formula (III) with a compound of formula (IV) (wherein A, B, D, E, G are as defined above for formula (I) or (II), and Z is Br, I) in the presence of copper iodide, proline and a base (such as potassium carbonate) in a suitable solvent (for example DMSO) at a suitably elevated temperature (such as 60-100°C, such as at around 80°C).




Alternatively a compound of formula (I) can be prepared by reacting a compound of formula (III) with a compound of formula (IV) (wherein A, B, D, E, G as defined above for formulae (I) or (II), and Z is Br, I) in the presence of a palladium salt (such as palladium acetate), a phosphine (such as BINAP or dicyclohexyl-(2',4',6'-triisopropylbiphenyl-2-yl)-phosphane) and a base (for example caesium carbonate), in a suitable solvent (for example toluene) at a suitably elevated temperature (for example 80 – 100°C).

A compound of formula (III) can be prepared by deprotecting a compound of formula (V):




for example using trifluoroacetic acid in a suitable solvent (such as dichloromethane); or using a source of hydrogen chloride in a suitable solvent (such as dioxane).

A compound of formula (V), wherein Q is hydrogen, can be prepared by reacting a compound of formula (VI):




with a compound of formula (VII):




in the presence of NaBH(OAc)<sub>3</sub> and acetic acid, in a suitable solvent (such as tetrahydrofuran or dichloromethane).

A compound of formula (V), wherein Q is hydroxy, can be prepared by reacting a compound of formula (VI) with a compound of formula (VIII):



5 in a suitable solvent (such as a C<sub>1-6</sub> aliphatic alcohol, for example ethanol) at room temperature.


A compound of formula (I) wherein A is CXYCO<sub>2</sub>R<sup>5</sup> can be prepared by reacting a compound of formula (IX):



10 with methyl methylthiomethyl sulfoxide or ethyl ethylthiomethyl sulfoxide in the presence of a base (such as sodium hydride), in a suitable solvent (for example THF), at a suitable temperature (such as in the range 10 to -20°C, for example 0°C), and treating the product resulting therefrom with HCl in R<sup>5</sup>OH.

15 A compound of formula (II), wherein A is CXYCN, can be prepared by reacting a compound of formula (IX) with toluenesulfonylmethyl isocyanide in the presence of a base (such as potassium *tert*-butoxide), in a suitable solvent (for example dimethoxyethane) at a temperature between -78°C and 0°C.


A compound of formula (IX) can be prepared by reacting a compound of formula (III) with a compound of formula (X):




20 in the presence of a base (for example potassium carbonate), in a suitable solvent (for example dimethylacetamide) at a temperature of 80 - 100°C.

A compound of formula (I) wherein XY is OCR<sup>10</sup>R<sup>11</sup>, OCR<sup>10</sup>R<sup>11</sup>CR<sup>12</sup>R<sup>13</sup> or OCR<sup>10</sup>R<sup>11</sup>CR<sup>12</sup>R<sup>13</sup>CR<sup>14</sup>R<sup>15</sup> can be prepared by reacting a compound of formula (XI),

wherein one of A, B, D, E, or G represents COH, with a compound of formula (XII), wherein L is halogen or a sulfonate ester (for example tosylate), and n and m are, independently, 0 or 1, in the presence of a base (for example potassium carbonate), in a suitable solvent (for example DMF) at ambient temperature (for example 10-30°C).




A compound of formula (XI) can be prepared by reacting a compound of formula (III) with a compound of formula (XIII)



wherein M is bromine or iodine and one of A, B, D, E, or G is COH, in the presence of copper iodide, proline and a base (for example potassium carbonate) in a suitable solvent (for example DMSO) at a suitable elevated temperature (such as in the range 60-100°C, for example around 80°C. (Note that it is preferred that the phenol is protected as an ether (such as a methyl ether) using methods of protection and deprotection described below).

Alternatively any procedure using a compound of formula (III) can be carried out under similar conditions with a compound of formula (XIV):



(wherein the hydroxy group is preferably protected). The resultant product can then be oxidised to an aldehyde (for example under Swern conditions), and then condensed with a compound of formula (VI) in the presence of NaBH(OAc)₃ and acetic acid, in a suitable solvent (such as tetrahydrofuran or dichloromethane) to give a compound of formula (I), (II), or (XI). Alternatively these steps can be conducted in a different order; for example it is possible to proceed via a compound of formula (IX) providing that reaction of the aromatic aldehyde occurred before the Swern oxidation to produce the aldehyde that is reductively aminated.

The preparation of various intermediates can be found in WO00/66559 and WO01/77101; alternatively they can be prepared by using or adapting literature methods.

Further compounds of formula (I) can be prepared by adaptation of: the routes described above, methods described in the art or the Examples recited below.

Compounds of formula (III) to (XIV) can be prepared by using or adapting methods described in the art. The preparation of various phenoxy piperidines is described  
5 in WO 01/77101.

In the above processes it may be desirable or necessary to protect an acid group or a hydroxy or other potentially reactive group. Suitable protecting groups and details of processes for adding and removing such groups may be found in "Protective Groups in Organic Synthesis", 3rd Edition (1999) by Greene and Wuts.

10 In another aspect the present invention provides processes for the preparation of compounds of formula (I).

The compounds of formula (I) have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CCR3) activity, and may be used in the treatment of autoimmune, inflammatory, proliferative or hyperproliferative diseases, or  
15 immunologically-mediated diseases (including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS)).

Examples of these conditions are:

- (1) (the respiratory tract) obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma {such as bronchial,  
20 allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)}; bronchitis {such as eosinophilic bronchitis}; acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or  
25 pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer's lung and related diseases; nasal polyposis; fibroid lung, idiopathic interstitial pneumonia, antitussive activity, treatment of chronic cough associated with inflammatory conditions of the airways or iatrogenic induced cough;
- 30 (2) (bone and joints) arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarthropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behçet's disease, Sjogren's syndrome or systemic sclerosis;

- (3) (skin and eyes) psoriasis, atopic dermatitis, contact dermatitis or other eczmatous dermatides, seborrhoetic dermatitis, lichen planus, pemphigus, bullous pemphigus, epidermolysis bullosa, urticaria, angiodermas, vasculitides erythemas, cutaneous eosinophilias, uveitis, alopecia areata, corneal ulcer or vernal conjunctivitis;
- 5 (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, irritable bowel disease or food-related allergies which have effects remote from the gut (for example migraine, rhinitis or eczema);
- 10 (5) (Allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea; or chronic graft versus host disease; and/or
- 15 (6) (other tissues or diseases) Alzheimer's disease, multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), periodontal disease, Sezary syndrome, idiopathic thrombocytopenia purpura or disorders of the menstrual cycle.

The compounds of formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof, are also H1 antagonists (and can, therefore, be used in the treatment of  
20 allergic disorders); and may also be used to control a sign and/or symptom of what is commonly referred to as a cold (for example a sign and/or symptom of a common cold or influenza or other associated respiratory virus infection).

According to a further feature of the present invention there is provided a method for treating a chemokine mediated disease state (especially a CCR3 mediated disease state)  
25 in a mammal, such as man, suffering from, or at risk of, said disease state, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof.

According to another feature of the present invention there is provided a method for  
30 antagonising H1 in a mammal, such as man, suffering from, or at risk of, an H1 mediated disease state, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof.

According to yet another feature of the present invention there is provided a method for treating a sign and/or symptom of what is commonly referred to as a cold in a mammal, such as man, suffering from, or at risk of, said disease state, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of  
5 a compound of the formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof.

The invention also provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof or a solvate thereof, for use in therapy.

In another aspect the invention provides the use of a compound of formula (I), or a  
10 pharmaceutically acceptable salt thereof or a solvate thereof, in the manufacture of a medicament for use in therapy (for example modulating chemokine receptor activity (especially CCR3 receptor activity), antagonising H1 or treating a sign and/or symptom of what is commonly referred to as a cold).

The invention further provides the use of a compound of formula (I), or a  
15 pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of:

- (1) (the respiratory tract) obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma  
20 (for example late asthma or airways hyper-responsiveness)}; bronchitis {such as eosinophilic bronchitis}; acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis  
25 nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer's lung and related diseases; nasal polyposis; fibroid lung, idiopathic interstitial pneumonia, antitussive activity, treatment of chronic cough associated with inflammatory conditions of the airways or iatrogenic induced cough;
- (2) (bone and joints) arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarthropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's  
30 disease), Behçet's disease, Sjogren's syndrome or systemic sclerosis;
- (3) (skin and eyes) psoriasis, atopic dermatitis, contact dermatitis or other eczmatous dermatides, seborrhoetic dermatitis, lichen planus, pemphigus, bullous pemphigus,

- epidermolysis bullosa, urticaria, angiodermas, vasculitides erythemas, cutaneous eosinophilias, uveitis, alopecia areata, corneal ulcer or vernal conjunctivitis;
- (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, irritable bowel disease or food-related allergies which have effects remote from the gut (for example migraine, rhinitis or eczema);
- (5) (Allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea; or chronic graft versus host disease; and/or
- (6) (other tissues or diseases) Alzheimer's disease, multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), Peridontal disease, sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle;
- in a mammal (for example man).

In a further aspect the invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)); or rhinitis {including acute, allergic, atrophic or chronic rhinitis, such as rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis}.

In a still further aspect a compound of formula (I), or a pharmaceutically acceptable salt thereof, is useful in the treatment of asthma.

The present invention also provides a the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)); or rhinitis {including acute, allergic, atrophic or chronic rhinitis, such as rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous

rhinitis or serofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis}.

In order to use a compound of the invention, or a pharmaceutically acceptable salt thereof or solvate thereof, for the therapeutic treatment of a mammal, such as man, said  
5 ingredient is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition. Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof or a solvate thereof (active ingredient), and a pharmaceutically acceptable adjuvant, diluent or carrier.

10 In a further aspect the present invention provides a process for the preparation of said composition which comprises mixing active ingredient with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will, for example, comprise from 0.05 to 99 %w (per cent by weight), such as from 0.05 to 80 %w, for example from 0.10 to 70 %w, such as from 0.10  
15 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by topical (such as to the lung and/or airways or to the skin), oral, rectal or parenteral administration. For  
20 these purposes the compounds of this invention may be formulated by means known in the art. A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 0.1mg and 1g of active ingredient.

Each patient may receive, for example, a dose of  $0.01\text{mgkg}^{-1}$  to  $100\text{mgkg}^{-1}$ , such as in the range of  $0.1\text{mgkg}^{-1}$  to  $20\text{mgkg}^{-1}$ , of the active ingredient administered, for example,  
25 1 to 4 times per day.

The invention further relates to combination therapies wherein a compound of formula (1) or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, or a pharmaceutical composition or formulation comprising a compound of  
30 formula (1) is administered concurrently or sequentially or as a combined preparation with another therapeutic agent or agents, for the treatment of one or more of the conditions listed.

In particular, for the treatment of the inflammatory diseases such as (but not restricted to) rheumatoid arthritis, osteoarthritis, asthma, allergic rhinitis, chronic



obstructive pulmonary disease (COPD), psoriasis, and inflammatory bowel disease, the compounds of the invention may be combined with agents such as:- Non-steroidal anti-inflammatory agents (hereinafter NSAIDs) including non-selective cyclo-oxygenase (COX)-1 / COX-2 inhibitors whether applied topically or systemically (such as piroxicam, diclofenac, propionic acids such as naproxen, flurbiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, azapropazone, pyrazolones such as phenylbutazone, salicylates such as aspirin); selective COX-2 inhibitors (such as meloxicam, celecoxib, rofecoxib, valdecoxib, lumarocoxib, parecoxib and etoricoxib); cyclo-oxygenase inhibiting nitric oxide donors (CINODs); glucocorticosteroids (whether administered by topical, oral, intramuscular, intravenous, or intra-articular routes); methotrexate, leflunomide; hydroxychloroquine, d-penicillamine, auranofin or other parenteral or oral gold preparations ; analgesics; diacerein; intra-articular therapies such as hyaluronic acid derivatives; and nutritional supplements such as glucosamine.

The present invention still further relates to the combination of a compound of the invention together with a cytokine or agonist or antagonist of cytokine function, (including agents which act on cytokine signalling pathways such as modulators of the SOCS system) including alpha-, beta-, and gamma-interferons; insulin-like growth factor type I (IGF-1); interleukins (IL) including IL1 to 17, and interleukin antagonists or inhibitors such as anakinra; tumour necrosis factor alpha (TNF- $\alpha$ ) inhibitors such as anti-TNF monoclonal antibodies (for example infliximab; adalimumab , and CDP-870) and TNF receptor antagonists including immunoglobulin molecules (such as etanercept) and low-molecular-weight agents such as pentoxifylline.

The present invention still further relates to the combination of a compound of the invention together with modulators of chemokine receptor function such as antagonists of CCR1, CCR2, CCR2A, CCR2B, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX<sub>3</sub>CR1 for the C-X<sub>3</sub>-C family.

The present invention still further relates to the combination of a compound of the invention together with an inhibitor of matrix metalloproteases (MMPs), i.e., the stromelysins, the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1

(MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11) and MMP-9 and MMP-12, including agents such as doxycycline.

The present invention still further relates to the combination of a compound of the invention together with a leukotriene biosynthesis inhibitor, 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist such as; zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761; N-(5-substituted)-thiophene-2-alkylsulfonamides; 2,6-di-tert-butylphenolhydrazones; methoxytetrahydropyrans such as Zeneca ZD-2138; the compound SB-210661; pyridinyl-substituted 2-cyanonaphthalene compounds such as L-739,010; 2-cyanoquinoline compounds such as L-746,530; indole and quinoline compounds such as MK-591, MK-886, and BAY x 1005.

The present invention still further relates to the combination of a compound of the invention together with a receptor antagonist for leukotrienes (LT) B<sub>4</sub>, LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub>, selected from the group consisting of the phenothiazin-3-1s such as L-651,392; amidino compounds such as CGS-25019c; benzoxalamines such as ontazolast; benzenecarboximidamides such as BIIL 284/260; and compounds such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A), and BAY x 7195.

The present invention still further relates to the combination of a compound of the invention together with a phosphodiesterase (PDE) inhibitor such as the methylxanthanines including theophylline and aminophylline; and selective PDE isoenzyme inhibitors including PDE4 inhibitors and inhibitors of the isoform PDE4D, and inhibitors of PDE5.

The present invention still further relates to the combination of a compound of the invention together with histamine type 1 receptor antagonists such as cetirizine, loratadine, desloratadine, fexofenadine, acrivastine, terfenadine, astemizole, azelastine, levocabastine, chlorpheniramine, promethazine, cyclizine, and mizolastine applied orally, topically or parenterally.

The present invention still further relates to the combination of a compound of the invention together with a proton pump inhibitor (such as omeprazole) or gastroprotective histamine type 2 receptor antagonist.

The present invention still further relates to the combination of a compound of the invention with antagonists of the histamine type 4 receptor.

The present invention still further relates to the combination of a compound of the invention together with an alpha-1/alpha-2 adrenoceptor agonist vasoconstrictor

sympathomimetic agent, such as propylhexedrine, phenylephrine, phenylpropanolamine, ephedrine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, tramazoline hydrochloride, and ethylnorepinephrine hydrochloride.

- 5           The present invention still further relates to the combination of a compound of the invention together with anticholinergic agents including muscarinic receptor (M1, M2, and M3) antagonists such as atropine, hyoscine, glycopyrrrolate, ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine, and telenzepine.

- 10           The present invention still further relates to the combination of a compound of the invention together with a beta-adrenoceptor agonist (including beta receptor subtypes 1-4) such as isoprenaline, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, and pirbuterol, including chiral enantiomers thereof.

- 15           The present invention still further relates to the combination of a compound of the invention together with a chromone, including sodium cromoglycate and nedocromil sodium.

          The present invention still further relates to the combination of a compound of the invention together with a glucocorticoid, such as flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, ciclesonide, and mometasone furoate.

- 20           The present invention still further relates to the combination of a compound of the invention together with an agent that modulate nuclear hormone receptors such as PPARs.

          The present invention still further relates to the combination of a compound of the invention together with an immunoglobulin (Ig) or Ig preparation or an antagonist or antibody modulating Ig function such as anti-IgE (e.g. omalizumab).

- 25           The present invention still further relates to the combination of a compound of the invention together with other systemic or topically-applied anti-inflammatory agents including thalidomide and derivatives, retinoids, dithranol, and calcipotriol.

- 30           The present invention still further relates to the combination of a compound of the invention together with combinations of aminosaliclates and sulfapyridine such as sulfasalazine, mesalazine, balsalazide, and olsalazine; and immunomodulatory agents such as the thiopurines, and corticosteroids such as budesonide.

          The present invention still further relates to the combination of a compound of the invention together with an antibacterial agent including penicillin derivatives,

tetracyclines, macrolides, beta-lactams, fluoroquinolones, metronidazole, and inhaled aminoglycosides; and antiviral agents including acyclovir, famciclovir, valaciclovir, ganciclovir, cidofovir; amantadine, rimantadine; ribavirin; zanamavir and oseltamavir; protease inhibitors such as indinavir, nelfinavir, ritonavir, and saquinavir; nucleoside  
5 reverse transcriptase inhibitors such as didanosine, lamivudine, stavudine, zalcitabine, zidovudine; non-nucleoside reverse transcriptase inhibitors such as nevirapine, efavirenz.

The present invention still further relates to the combination of a compound of the invention together with cardiovascular agents such as calcium channel blockers, beta-adrenoceptor blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-2  
10 receptor antagonists; lipid lowering agents such as statins, and fibrates; modulators of blood cell morphology such as pentoxifylline; thrombolytics, and anticoagulants including platelet aggregation inhibitors.

The present invention still further relates to the combination of a compound of the invention together with CNS agents such as antidepressants (such as sertraline), anti-  
15 Parkinsonian drugs (such as deprenyl, L-dopa, ropinirole, pramipexole, MAOB inhibitors such as selegine and rasagiline, comP inhibitors such as tasmar, A-2 inhibitors, dopamine reuptake inhibitors, NMDA antagonists, nicotine agonists, dopamine agonists and inhibitors of neuronal nitric oxide synthase), and anti-Alzheimer's drugs such as donepezil, rivastigmine, tacrine, COX-2 inhibitors, propentofylline or metrifonate.

20 The present invention still further relates to the combination of a compound of the invention together with agents for the treatment of acute and chronic pain, including centrally and peripherally-acting analgesics such as opioid analogues and derivatives, carbamazepine, phenytoin, sodium valproate, amitryptiline and other antidepressant agents, paracetamol, and non-steroidal anti-inflammatory agents.

25 The present invention still further relates to the combination of a compound of the invention together with parenterally or topically-applied (including inhaled) local anaesthetic agents such as lignocaine and analogues.

The compounds of the present invention may also be used in combination with anti-osteoporosis agents including hormonal agents such as raloxifene, and biphosphonates  
30 such as alendronate.

The present invention still further relates to the combination of a compound of the invention together with (i) tryptase inhibitors; (ii) platelet activating factor (PAF) antagonists; (iii) interleukin converting enzyme (ICE) inhibitors; (iv) IMPDH inhibitors;

- (v) adhesion molecule inhibitors including VLA-4 antagonists; (vi) cathepsins; (vii) Kinase inhibitors including but not limited to inhibitors of tyrosine kinases (such as Btk, Itk, Jak3 MAP examples of inhibitors might include Gefitinib, Imatinib mesylate), Serine / threonine kinases (including but not limited to inhibitors of MAP kinases such as p38, JNK, protein kinases A, B and C and IKK), and kinases involved in cell cycle regulation (such as but not limited to the cyclin dependent kinases); (viii) glucose-6 phosphate dehydrogenase inhibitors; (ix) kinin-B<sub>1</sub> - and B<sub>2</sub> -receptor antagonists; (x) anti-gout agents, e.g., colchicine; (xi) xanthine oxidase inhibitors, e.g., allopurinol; (xii) uricosuric agents, e.g., probenecid, sulfinpyrazone, and benzbromarone; (xiii) growth hormone secretagogues; (xiv) transforming growth factor (TGF $\beta$ ); (xv) platelet-derived growth factor (PDGF); (xvi) fibroblast growth factor, e.g., basic fibroblast growth factor (bFGF); (xvii) granulocyte macrophage colony stimulating factor (GM-CSF); (xviii) capsaicin cream; (xix) tachykinin NK<sub>1</sub> and NK<sub>3</sub> receptor antagonists such as the group consisting of NKP-608C; SB-233412 (talnetant); and D-4418; (xx) elastase inhibitors such as the group consisting of UT-77 and ZD-0892; (xxi) TNF-alpha converting enzyme inhibitors (TACE); (xxii) induced nitric oxide synthase (iNOS) inhibitors or (xxiii) chemoattractant receptor-homologous molecule expressed on TH2 cells, (such as CCR2 antagonists) (xxiv) inhibitors of P38 (xxv) agents modulating the function of Toll-like receptors (TLR) and (xxvi) agents modulating the activity of purinergic receptors such as P2X7; (xxvii) inhibitors of transcription factors activation such as NF $\kappa$ B, API, and STATS.

The compounds of the invention can also be used in combination with existing therapeutic agents for the treatment of cancer. Suitable agents to be used in combination include:

- (i) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, gemcitabine and paclitaxel; antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere); and

topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecins);

(ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and idoxifene), oestrogen receptor down regulators (for example fulvestrant), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuporelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5 $\alpha$ -reductase such as finasteride;

- 10 (iii) Agents which inhibit cancer cell invasion (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function);
- (iv) inhibitors of growth factor function, for example such inhibitors include growth factor antibodies, growth factor receptor antibodies (for example the anti-erbB2 antibody trastuzumab and the anti-erbB1 antibody cetuximab [C225]), farnesyl transferase
- 15 inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, AZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-(3-
- 20 chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033)), for example inhibitors of the platelet-derived growth factor family and for example inhibitors of the hepatocyte growth factor family;
- (v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, (for example the anti-vascular endothelial cell growth factor antibody
- 25 bevacizumab, compounds such as those disclosed in International Patent Applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and compounds that work by other mechanisms (for example linomide, inhibitors of integrin  $\alpha v \beta 3$  function and angiostatin);
- (vi) vascular damaging agents such as combretastatin A4 and compounds disclosed in
- 30 International Patent Applications WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213;
- (vii) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense;

- (viii) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and
- (ix) immunotherapeutic approaches, including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.

The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:

- (i) when given,  $^1\text{H}$  NMR data is quoted and is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300MHz or 400MHz using perdeuterio DMSO-D6 ( $\text{CD}_3\text{SOCD}_3$ ) or  $\text{CDCl}_3$  as the solvent unless otherwise stated;
- (ii) mass spectra (MS) were run with an electron energy of 70 electron volts in the chemical ionisation (CI) mode using a direct exposure probe; where indicated ionisation was effected by electron impact (EI) or fast atom bombardment (FAB); where values for  $m/z$  are given, generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion -  $(\text{M}+\text{H})^+$ ;
- (iii) the title and sub-title compounds of the examples and methods were named using the ACD/name program from Advanced Chemistry Development Inc, version 6.00;
- (iv) unless stated otherwise, reverse phase HPLC was conducted using a Symmetry<sup>TM</sup>, NovaPak<sup>TM</sup> or Xerra<sup>TM</sup> reverse phase silica column;
- (v) for analytical HPLC the following conditions were used:
- Reverse phase analytical HPLC (Hewlett Packard Series 1100) using Waters "Symmetry" C8 column 3.5 $\mu\text{m}$ ; 4.6 x 50mm column using 0.1% ammonium acetate/acetonitrile gradients at 2 mL/min given as % aqueous
- Standard 75% to 5% over 3 min
- Fast 45% to 5% over 2.5 min
- Medium fast 65% to 5% in 2.5 min

Slow 95% to 50% in 2.5 min

Superslow 100% to 80% in 2.5 min;

Other gradients are reported as aqueous/starting % aq/final % aq/organic/time (in minutes) where NH4 represents 0.1% ammonium acetate and A represents acetonitrile;

5 and

(vi) the following abbreviations are used:

RPHPLC	Reverse phase HPLC	DMSO	dimethylsulfoxide
HPLC	high pressure liquid chromatography	aq	aqueous
TFA	Trifluoroacetic acid	RT	room temperature
DMF	N,N-dimethylformamide	TBME	<u>tert</u> -butyl methyl ether
Ret	Retention time.		

#### Intermediate 1

This illustrates the preparation of 4-(3,4-dichlorophenoxy)-1-(4-piperidinylmethyl)-  
10 piperidine

a) 1,1-Dimethylethyl 4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinecarboxylate

4-(3,4-Dichlorophenoxy)piperidine (1.27 g) was dissolved in tetrahydrofuran (20 mL); acetic acid (0.5 mL) and *tert*-butyl 4-formylpiperidine-1-carboxylate (1.43 g) were  
15 added to the solution. The reaction mixture was stirred at room temperature for 30 min then sodium triacetoxymethylborohydride (1.53 g) was added and the mixture was stirred at room temperature overnight. The reaction mixture was poured into 2M sodium hydroxide solution (50 mL) and product was extracted with diethyl ether. The combined ether extracts were washed with brine, dried, filtered and evaporated. Crude material was  
20 purified by flash chromatography, (eluting with 979:20:1 dichloromethane : methanol : aqueous ammonia) to give the sub-title compound (2.15 g).

MS 443/445 [M+H]<sup>+</sup> (ES<sup>+</sup>)

<sup>1</sup>H NMR  $\delta$  (CDCl<sub>3</sub>) 1.06 (2H, ddd), 1.45 (9H, s), 1.61 - 1.82 (5H, m), 1.92 - 1.98 (2H, m), 2.16 - 2.27 (4H, m), 2.65 - 2.73 (4H, m), 4.08 (2H, d), 4.25 (1H, dq), 6.75 (1H, dd), 6.99 (1H, d), 7.30 (1H, d)  
25

b) 4-(3,4-Dichlorophenoxy)-1-(4-piperidinylmethyl)-piperidine



1,1-Dimethylethyl 4-{{[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl}piperidine-1-carboxylate (1.0 g) was added to a mixture of 20% TFA in dichloromethane (20 mL) and the mixture was stirred at room temperature for 1 h. Solvent was removed by evaporation and 2M sodium hydroxide solution (25 mL) was added to the residue. The product was  
 5 extracted with ethyl acetate and the organic phase was washed with brine, dried, filtered and evaporated to give the title compound (0.5 g).

MS 343/345 [M+H]<sup>+</sup> (ES<sup>+</sup>)

<sup>1</sup>H NMR δ (CDCl<sub>3</sub>) 1.10 (2H, qd), 1.60 (1H, qquintet), 1.73 - 1.83 (4H, m), 1.90 - 2.01 (2H, m), 2.16 - 2.26 (4H, m), 2.55 - 2.70 (4H, m), 3.09 (2H, d), 4.24 (1H, dqintet),  
 10 6.75 (1H, dd), 6.99 (1H, d), 7.27 (1H, d).

The following Intermediates were prepared analogously from the appropriate aryloxy piperidine:

Intermediate	Name (M+H)	<sup>1</sup> H NMR δ (CDCl <sub>3</sub> )
2	4-(2,4-Dichloro-3-methylphenoxy)-1-(4-piperidinylmethyl)-piperidine (357/359)	1.13 - 1.27 (2H, m), 1.57 - 1.70 (1H, m), 1.76 - 2.00 (2H, m), 2.16 - 2.32 (4H, m), 2.46 (3H, s), 2.60 - 2.99 (8H, m), 3.16 (2H, d), 4.31 (1H, quintet), 6.75 (1H, d), 7.18 (1H, d)
3	4-(4-Chloro-2-methylphenoxy)-1-(4-piperidinylmethyl)-piperidine (322/324)	1.08 - 1.21 (2H, m), 1.56 - 1.68 (1H, m), 1.73 - 1.86 (4H, m), 1.90 - 1.99 (2H, m), 2.16 - 2.31 (7H, m), 2.57 - 2.69 (4H, m), 3.12 (2H, d), 4.23 - 4.31 (1H, m), 6.74 (1H, d), 7.06 (1H, dd), 7.11 (1H, d)

#### Intermediate 4

This illustrates the preparation of 2-(4-{{[4-(3,4-Dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl})phenol

4-(3,4-Dichlorophenoxy)-1-{{[1-(2-methoxyphenyl)piperidin-4-yl]methyl}piperidine

4-(3,4-Dichlorophenoxy)-1-(piperidin-4-ylmethyl)piperidine (1.0 g), 1-iodo-2-methoxybenzene (0.68 g), copper iodide (55 mg), L-proline (66 mg) and K<sub>2</sub>CO<sub>3</sub> (0.8 g) were suspended in DMSO and heated to 80 °C for 16 h. The mixture was diluted with

water and then extracted using EtOAc (3x 100 mL). The organic layers were combined, washed with brine, dried and the solvents were evaporated. The residue was purified by chromatography (EtOAc) to give the subtitle compound (0.20 g)

HPLC Ret. standard. 2.9

5 MS (ES+ve) 449/451 (M+H)<sup>+</sup>

2-(4-{[4-(3,4-Dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenol

4-(3,4-Dichlorophenoxy)-1-{[1-(2-methoxyphenyl)piperidin-4-yl]methyl}piperidine (0.15 g) was dissolved in dichloromethane (2 mL) and the solution  
10 was cooled to -30 °C in an ice bath (dry ice/Acetonitrile). Tribromoborane (1M solution in dichloromethane, 2.6 mL) was added. The reaction mixture was allowed to warm to 0 °C over 4 h. Methanol (2 mL) was carefully added while the reaction mixture was kept at 0 °C. The solvents were evaporated and the residue was dissolved in MeOH and then purified by RPHPLC (gradient 75% - 5% aqueous ammonium acetate, 25% - 95%  
15 acetonitrile) to give the subtitle compound (100 mg).

HPLC Ret. fast 2.02

MS (ES+ve) 435/437 (M+H)<sup>+</sup>

20 The following intermediate was prepared analogously to Intermediate 4 using the appropriate iodophenol

Intermediate	Name	MS (ES+ve) (M+H) <sup>+</sup>	Retention time gradient
5	2-(4-{[4-(3,4-Dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenol	435/437	2.75 std

### EXAMPLE 1

This Example illustrates the preparation of methyl [3-(4-{[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenyl]acetate

25 4-(3,4-Dichlorophenoxy)-1-(piperidin-4-ylmethyl)piperidine (0.7 g), methyl (3-bromophenyl)acetate (0.5g), copper iodide (38 mg), L-proline (23mg) and K<sub>2</sub>CO<sub>3</sub> (0.8g) were suspended in DMSO and heated to 85 °C for 16 h. The mixture was diluted with

water and then extracted using EtOAc (3x 100 mL). The organic layers were combined, washed with brine, dried and the solvents were evaporated. The residue was purified by chromatography (EtOAc) to give the title compound (0.19 g)

HPLC Ret. standard 2.98

5 MS (ES+) 491/493 (M+H)<sup>+</sup>

Examples 2 to 8 and 13 (Table I below) were prepared by the same method as Example 1 using the appropriate aryl bromide or iodide.

10

#### EXAMPLE 9

This Example illustrates the preparation of methyl (2*R*)-2-[2-(4-{[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenoxy]propanoate

2-(4-{[4-(3,4-Dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenol (100 mg) and K<sub>2</sub>CO<sub>3</sub> (44 mg) were suspended in DMF (3 mL) and stirred for 15 min. Methyl (2*S*)-2-[[4-(4-methylphenyl)sulfonyl]oxy]propanoate (65 mg) was added and the reaction mixture was heated to 65 °C for 18 h. The mixture was diluted with water and then extracted using TBME (3x 20 mL). The organic layers were combined, washed with bicarbonate solution, dried and the solvents were evaporated. The residue was purified by RPHPLC (gradient 75% - 5% aqueous ammonium acetate, 25% - 95% acetonitrile) to give the subtitle compound (100 mg).

20

HPLC Ret. standard 3.28

MS (ES+ve) 521/523 (M+H)<sup>+</sup>

Examples 10 to 12 (Table I below) were prepared by the same method as Example 9 using the appropriate phenol and tosylate.

25

#### EXAMPLE 14

This Example illustrates the preparation of methyl [4-(4-{[4-(3,4-dichloro-2-methylphenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenyl]acetate

30

4-(3,4-Dichloro-2-methylphenoxy)-1-(piperidin-4-ylmethyl)piperidine (200 mg), methyl (4-bromophenyl)acetate (128 mg), Cs<sub>2</sub>CO<sub>3</sub> (273 mg), palladium acetate (5 mg) and dicyclohexyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphone (12 mg) were combined and purged with nitrogen for 3 mins. The reaction mixture was suspended in toluene (3 mL)

and heated to 100 °C for 16 h. The mixture was diluted with water and then extracted using EtOAc (3x 100 mL). The organic layers were combined, washed with H<sub>2</sub>O, dried and the solvents were evaporated. The residue was purified by chromatography (iso-hexane/EtOAc, 1/1 to neat EtOAc) to give the title compound (210 mg).

5 HPLC Ret. standard. 3.04

MS (ES+ve) 505/507 (M+H)<sup>+</sup>

Examples 15 & 16 (Table I below) were prepared by the same method as Example 14 using the appropriate aryl bromide and amine.

10

Table I.

Example	Name	MS [M+H] <sup>+</sup> (ES+)	Retention time gradient
2	Methyl [2-(4-{[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenyl]acetate	491/493	2.95 standard
3	Methyl [4-(4-{[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenyl]acetate	491/493	1.21 fast
4	Methyl [3-(4-{[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)-4-methoxyphenyl]acetate	521/523	2.77 standard
5	<i>tert</i> -Butyl [2-(4-{[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenoxy]acetate	549/551	2.66 fast
6	<i>tert</i> -Butyl [3-(4-{[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenoxy]acetate	549/551	2.48 fast
7	<i>tert</i> -Butyl [4-(4-{[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenoxy]acetate	549/551	1.95 fast
8	<i>tert</i> -Butyl 2-[2-(4-{[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl}piperidin-	577/579	3.01 fast

	1-yl)phenoxy]-2-methylpropanoate		
10	Methyl (2 <i>S</i> )-2-[2-(4-{[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenoxy]propanoate	521/523	3.17 standard
11	Methyl (2 <i>R</i> )-2-[3-(4-{[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenoxy]propanoate	521/523	3.15 standard
12	Methyl (2 <i>S</i> )-2-[3-(4-{[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenoxy]propanoate	521/523	3.10 standard
13	Methyl 3-[2-(4-{[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenyl]propanoate	505/507	3.01 standard
15	Methyl [4-(4-{[4-(2,4-dichloro-3-methylphenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenyl]acetate	505/507	2.98 standard
16	Methyl [3-(4-{[4-(2,4-dichloro-3-methylphenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenyl]acetate	505/507	3.03 standard

### EXAMPLE 17

This Example illustrates the preparation of [3-(4-{[4-(3,4-Dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenyl]acetic acid

5 Methyl [3-(4-{[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenyl]acetate (0.19 g) was suspended in MeOH/H<sub>2</sub>O (4/1, 5mL) and LiOH (25mg) was added. The mixture was heated to 85 °C for 2h. The reaction was allowed to cool and the solvents were evaporated. The residue was dissolved in MeOH and acidified with AcOH and then purified by RPHPLC (gradient 95% - 50% aqueous ammonium acetate, 5% - 50%  
10 acetonitrile) to give the title compound (76 mg).

HPLC Ret. fast 0.42

MS (ES<sup>+</sup>) 477/479 (M+H)<sup>+</sup>

<sup>1</sup>H NMR δ<sub>(CD<sub>3</sub>OD+NaOD)</sub> 1.28 - 1.40 (2H, m), 1.63 - 1.82 (3H, m), 1.82 - 1.91 (2H, m), 1.96 - 2.05 (2H, m), 2.25 - 2.37 (4H, m), 2.62 - 2.78 (4H, m), 3.42 (2H, s), 3.62 - 3.68 (2H, m),

4.35 - 4.43 (1H, m), 6.79 - 6.84 (2H, m), 6.89 (1H, dd), 6.98 - 7.01 (1H, m), 7.08 - 7.14 (2H, m), 7.37 (1H, d).

5        Examples 17 to 19 and 23 to 30 (Table II below) were prepared by the same method as Example 16.

#### EXAMPLE 21

This Example illustrates the preparation of [2-(4-{[4-(3,4-Dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenoxy]acetic acid

10        *tert*-Butyl [2-(4-{[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenoxy]acetate (0.11 g) was dissolved in dichloromethane (5 mL) and TFA (5 mL) was added. The solution was stirred at RT for 16 h. The solvents were evaporated. The residue was dissolved in MeOH and then purified by RPHPLC (gradient 95% - 50% aqueous ammonium acetate, 5% - 50% acetonitrile) to give the title compound (64 mg).

15        HPLC Ret. fast 0.50

MS (ES+ve) 493/495 (M+H)<sup>+</sup>

<sup>1</sup>H NMR  $\delta_{(\text{CD}_3\text{OD}+\text{NaOD})}$  1.38 - 1.50 (2H, m), 1.63 - 1.88 (5H, m), 1.96 - 2.04 (2H, m), 2.26 - 2.37 (4H, m), 2.53 - 2.62 (2H, m), 2.70 - 2.78 (2H, m), 3.50 - 3.57 (2H, m), 4.35 - 4.43 (1H, m), 4.45 (2H, s), 6.83 - 6.94 (4H, m), 6.95 - 6.99 (1H, m), 7.09 (1H, d), 7.37 (1H, d).

20

Examples 22 and 23 (Table II below) were prepared by the same method as Example 20.

Table II

Example	Name	MS [M+H] <sup>+</sup> (ES+)	Retention time gradient	<sup>1</sup> H NMR
18	[2-(4-{[4-(3,4-Dichlorophenoxy)piperidin-1-yl]phenyl}acetic acid	477/479	0.59 fast	$\delta_{(\text{CD}_3\text{OD}+\text{NaOD})}$ 1.37 - 1.50 (2H, m), 1.55 - 1.69 (1H, m), 1.71 - 1.86 (4H, m), 1.97 - 2.06 (2H, m), 2.28 - 2.38 (4H, m), 2.60 - 2.68 (2H, m), 2.70 - 2.80 (2H, m), 3.07 - 3.14 (2H, m), 3.62 (2H, s), 4.35 - 4.43 (1H, m), 6.89 (1H, dd), 6.94 - 6.99 (1H, m), 7.04 - 7.07 (1H, m), 7.09 - 7.14 (2H, m), 7.25 - 7.29 (1H, m), 7.37 (1H, d)
19	[4-(4-{[4-(3,4-Dichlorophenoxy)piperidin-1-yl]phenyl}acetic acid	477/479	1.82 standard	$\delta_{(\text{CD}_3\text{OD}+\text{NaOD})}$ 1.30 - 1.45 (2H, m), 1.60 - 1.94 (5H, m), 1.97 - 2.08 (2H, m), 2.27 - 2.41 (4H, m), 2.61 - 2.82 (4H, m), 3.40 (2H, s), 3.57 - 3.65 (2H, m), 4.37 - 4.46 (1H, m), 6.88 - 6.97 (3H, m), 7.11 - 7.14 (1H, m), 7.19 - 7.24 (2H, m), 7.37 - 7.42 (1H, m)
20	[3-(4-{[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-4-methoxyphenyl}acetic acid	507/509	2.40 NH4/85/30/A/5	$\delta_{(\text{CD}_3\text{OD}+\text{NaOD})}$ 1.27 - 1.48 (2H, m), 1.61 - 1.89 (5H, m), 1.96 - 2.06 (2H, m), 2.26 - 2.39 (4H, m), 2.53 - 2.62 (2H, m), 2.70 - 2.79 (2H, m), 3.36 - 3.44 (4H, m), 3.83 (3H, s), 4.36 - 4.43 (1H, m), 6.83 (1H, d), 6.89 (1H, dd), 6.93 - 6.96 (1H, m), 7.01 (1H, d), 7.10 (1H, d), 7.37 (1H, d)

22	[3-(4-{[4-(3,4-Dichlorophenoxy)piperidin-1-yl]methoxy}phenyl)acetic acid	493/495	1.66 standard	$\delta_{(\text{CD}_3\text{OD}+\text{NaOD})}$ 1.28 - 1.44 (2H, m), 1.60 - 1.93 (5H, m), 1.98 - 2.10 (2H, m), 2.26 - 2.41 (4H, m), 2.63 - 2.81 (4H, m), 3.64 - 3.71 (2H, m), 4.36 (2H, s), 4.37 - 4.46 (1H, m), 6.41 - 6.46 (1H, m), 6.56 - 6.63 (2H, m), 6.91 (1H, dd), 7.04 - 7.19 (2H, m), 7.40 (1H, d)
23	[4-(4-{[4-(3,4-Dichlorophenoxy)piperidin-1-yl]methoxy}phenyl)acetic acid	493/495	0.60 fast	$\delta_{(\text{CD}_3\text{OD}+\text{NaOD})}$ 1.31 - 1.46 (2H, m), 1.59 - 1.95 (5H, m), 1.97 - 2.08 (2H, m), 2.28 - 2.40 (4H, m), 2.57 - 2.68 (2H, m), 2.71 - 2.81 (2H, m), 3.44 - 3.52 (2H, m), 4.33 (2H, s), 4.37 - 4.46 (1H, m), 6.86 - 6.93 (3H, m), 6.95 - 7.01 (2H, m), 7.12 (1H, d), 7.40 (1H, d)
24	2-[2-(4-{[4-(3,4-Dichlorophenoxy)piperidin-1-yl]methoxy}-2-methylpropanoic acid	521/523	0.61 fast	$\delta_{(\text{CD}_3\text{OD}+\text{NaOD})}$ 1.38 - 1.48 (2H, m), 1.54 (6H, s), 1.64 - 1.88 (5H, m), 1.97 - 2.05 (2H, m), 2.28 - 2.38 (4H, m), 2.51 - 2.59 (2H, m), 2.70 - 2.79 (2H, m), 3.51 - 3.58 (2H, m), 4.36 - 4.43 (1H, m), 6.78 - 6.84 (2H, m), 6.87 - 6.96 (3H, m), 7.10 (1H, d), 7.38 (1H, d)
25	(2R)-2-[2-(4-{[4-(3,4-Dichlorophenoxy)piperidin-1-yl]methoxy}phenyl)propanoic acid	507/509	1.66 standard	$\delta_{(\text{CD}_3\text{OD}+\text{NaOD})}$ 1.28 - 1.50 (2H, m), 1.56 (3H, s), 1.59 - 1.90 (5H, m), 1.97 - 2.06 (2H, m), 2.28 - 2.38 (4H, m), 2.42 - 2.51 (1H, m), 2.62 - 2.70 (1H, m), 2.71 - 2.79 (2H, m), 3.35 - 3.42 (1H, m), 3.76 - 3.83 (1H, m), 4.36 - 4.43 (1H, m), 4.53 (1H, q), 6.80 - 6.96 (5H, m), 7.10 (1H, d), 7.37 (1H, d)



26	(2S)-2-[2-(4-{[4-(3,4-Dichlorophenoxy)piperidin-1-yl]methoxy}piperidin-1-yl)phenoxy]propanoic acid	507/509	1.60 standard	$\delta_{(\text{CD}_3\text{OD}+\text{NaOD})}$ 1.27 - 1.48 (2H, m), 1.56 (3H, d), 1.60 - 1.90 (5H, m), 1.96 - 2.05 (2H, m), 2.27 - 2.38 (4H, m), 2.43 - 2.51 (1H, m), 2.62 - 2.71 (1H, m), 2.71 - 2.79 (2H, m), 3.35 - 3.42 (1H, m), 3.76 - 3.83 (1H, m), 4.36 - 4.43 (1H, m), 4.53 (1H, q), 6.80 - 6.91 (4H, m), 6.92 - 6.95 (1H, m), 7.10 (1H, d), 7.37 (1H, d)
27	(2R)-2-[3-(4-{[4-(3,4-Dichlorophenoxy)piperidin-1-yl]methoxy}piperidin-1-yl)phenoxy]propanoic acid	507/509	1.51 standard	$\delta_{(\text{CD}_3\text{OD}+\text{NaOD})}$ 1.26 - 1.40 (2H, m), 1.50 (3H, d), 1.63 - 1.90 (5H, m), 1.96 - 2.05 (2H, m), 2.24 - 2.38 (4H, m), 2.60 - 2.78 (4H, m), 3.59 - 3.67 (2H, m), 4.35 - 4.43 (1H, m), 4.47 (1H, q), 6.37 - 6.41 (1H, m), 6.51 - 6.56 (2H, m), 6.89 (1H, dd), 7.06 (1H, t), 7.09 (1H, d), 7.37 (1H, d)
28	(2S)-2-[3-(4-{[4-(3,4-Dichlorophenoxy)piperidin-1-yl]methoxy}piperidin-1-yl)phenoxy]propanoic acid	507/509	1.50 standard	$\delta_{(\text{CD}_3\text{OD})}$ 1.26 - 1.40 (3H, m), 1.50 (3H, d), 1.63 - 1.90 (5H, m), 1.96 - 2.05 (2H, m), 2.24 - 2.37 (4H, m), 2.61 - 2.69 (2H, m), 2.70 - 2.77 (2H, m), 3.60 - 3.66 (2H, m), 4.35 - 4.42 (1H, m), 6.37 - 6.41 (1H, m), 6.51 - 6.56 (2H, m), 6.89 (1H, dd), 7.05 (1H, t), 7.09 (1H, d), 7.37 (1H, d)

29	3-[2-(4-{[4-(3,4-Dichlorophenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenyl]propanoic acid	491/493	1.95 standard	$\delta_{(\text{CD}_3\text{OD}+\text{NaOD})}$ 1.26 - 1.50 (2H, m), 1.59 - 1.87 (5H, m), 1.96 - 2.06 (2H, m), 2.27 - 2.40 (4H, m), 2.42 - 2.50 (2H, m), 2.61 - 2.79 (4H, m), 2.93 - 3.00 (2H, m), 3.01 - 3.07 (2H, m), 4.36 - 4.44 (1H, m), 6.89 (1H, dd), 6.93 - 6.98 (1H, m), 7.06 - 7.11 (3H, m), 7.21 (1H, d), 7.38 (1H, d)
30	[4-(4-{[4-(3,4-Dichloro-2-methylphenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenyl]acetic acid	491/493	1.71 standard	$\delta_{(\text{CD}_3\text{OD}+\text{NaOD})}$ 1.28 - 1.46 (2H, m), 1.61 - 1.96 (5H, m), 1.97 - 2.11 (2H, m), 2.23 - 2.47 (4H, m), 2.34 (3H, s), 2.60 - 2.78 (4H, m), 3.40 (2H, s), 3.56 - 3.65 (2H, m), 4.41 - 4.50 (1H, m), 6.89 - 7.00 (3H, m), 7.18 - 7.34 (3H, m)
31	[4-(4-{[4-(2,4-Dichloro-3-methylphenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenyl]acetic acid	491/493	1.65 standard	$\delta_{(\text{CD}_3\text{OD}+\text{NaOD})}$ 1.29 - 1.46 (2H, m), 1.63 - 1.78 (1H, m), 1.80 - 1.95 (4H, m), 1.96 - 2.09 (2H, m), 2.26 - 2.34 (2H, m), 2.36 - 2.45 (2H, m), 2.47 (3H, s), 2.59 - 2.81 (4H, m), 3.40 (2H, s), 3.52 - 3.70 (2H, m), 4.43 - 4.56 (1H, m), 6.89 - 7.03 (3H, m), 7.16 - 7.33 (3H, m)
32	[3-(4-{[4-(2,4-Dichloro-3-methylphenoxy)piperidin-1-yl]methyl}piperidin-1-yl)phenyl]acetic acid	491/493	1.65 standard	$\delta_{(\text{CD}_3\text{OD}+\text{NaOD})}$ 1.29 - 1.44 (2H, m), 1.63 - 1.78 (1H, m), 1.80 - 1.95 (4H, m), 1.96 - 2.09 (2H, m), 2.28 - 2.33 (2H, m), 2.34 - 2.45 (2H, m), 2.47 (3H, s), 2.63 - 2.81 (4H, m), 3.44 (2H, s), 3.63 - 3.72 (2H, m), 4.44 - 4.53 (1H, m), 6.81 - 6.87 (2H, m), 6.97 (1H, d), 7.00 - 7.03 (1H, m), 7.14 (1H, t), 7.28 (1H, d)

### EXAMPLE 33

### Pharmacological Analysis: Calcium flux $[Ca^{2+}]_i$ assay

## Human eosinophils

Human eosinophils were isolated from EDTA anticoagulated peripheral blood as previously described (Hansel et al., *J. Immunol. Methods*, 1991, 145, 105-110). The cells were resuspended ( $5 \times 10^6 \text{ ml}^{-1}$ ) and loaded with  $5 \mu\text{M}$  FLUO-3/AM + Pluronic F127  $2.2 \mu\text{l/ml}$  (Molecular Probes) in low potassium solution (LKS; NaCl 118mM,  $\text{MgSO}_4$  0.8mM, glucose 5.5mM,  $\text{Na}_2\text{CO}_3$  8.5mM, KCl 5mM, HEPES 20mM,  $\text{CaCl}_2$  1.8mM, BSA 0.1%, pH 7.4) for one hour at room temperature. After loading, cells were centrifuged at 200g for 5min and resuspended in LKS at  $2.5 \times 10^6 \text{ ml}^{-1}$ . The cells were then transferred to 96 well FLIPr plates (Poly-D-Lysine plates from Becton Dickinson pre-incubated with  $5 \mu\text{M}$  fibronectin for two hours) at  $25 \mu\text{l/well}$ . The plate was centrifuged at 200g for 5min and the cells were washed twice with LKS ( $200 \mu\text{l}$ ; room temperature).

15 A compound of the Examples was pre-dissolved in DMSO and added to a final concentration of 0.1%(v/v) DMSO. Assays were initiated by the addition of an A<sub>50</sub> concentration of eotaxin and the transient increase in fluo-3 fluorescence ( $I_{EX}$  = 490nm and  $I_{EM}$  = 520nm) monitored using a FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices, Sunnyvale, U.S.A.).

Compounds of the Examples were found to be antagonists if the increase in fluorescence induced by eotaxin (a selective CCR3 agonist) was inhibited in a concentration dependent manner. The concentration of antagonist required to inhibit the fluorescence by 50% can be used to determine the  $IC_{50}$  for the antagonist at the CCR3 receptor.

### EXAMPLE 34

## Human eosinophil chemotaxis

Human eosinophils were isolated from EDTA anticoagulated peripheral blood as previously described (Hansel et al., *J. Immunol. Methods*, 1991, 145, 105-110). The cells were resuspended at  $10 \times 10^6 \text{ ml}^{-1}$  in RPMI containing 200 IU/ml penicillin, 200  $\mu\text{g/ml}$  streptomycin sulfate and supplemented with 10% HIFCS, at room temperature.

Eosinophils (700  $\mu$ l) were pre-incubated for 15 mins at 37° C with 7  $\mu$ l of either vehicle or compound (100x required final concentration in 10% DMSO). The chemotaxis

plate (ChemoTx, 3µm pore, Neuroprobe) was loaded by adding 28µl of a concentration of eotaxin 0.1 to 100nM (a selective CCR3 agonist over this concentration range) containing a concentration of a compound according to the Examples or solvent to the lower wells of the chemotaxis plate. The filter was then placed over the wells and 25 µl of eosinophil suspension were added to the top of the filter. The plate was incubated for 1 hr at 37° C in a humidified incubator with a 95% air/5% CO<sub>2</sub> atmosphere to allow chemotaxis.

The medium, containing cells that had not migrated, was carefully aspirated from above the filter and discarded. The filter was washed once with phosphate buffered saline (PBS) containing 5 mM EDTA to remove any adherent cells. Cells that had migrated through the filter were pelleted by centrifugation (300xg for 5 mins at room temperature) and the filter removed and the supernatant transferred to each well of a 96-well plate (Costar). The pelleted cells were lysed by the addition of 28 µl of PBS containing 0.5% Triton x100 followed by two cycles of freeze/thawing. The cell lysate was then added to the supernatant. The number of eosinophils migrating was quantified according to the method of Strath et al., *J. Immunol. Methods*, 1985, 83, 209 by measuring eosinophil peroxidase activity in the supernatant.

Compounds of the Examples were found to be antagonists of eotaxin mediated human eosinophil chemotaxis if the concentration response to eotaxin was shifted to the right of the control curve. Measuring the concentration of eotaxin required to give 50% chemotaxis in the presence or absence of compounds enables the apparent affinity of the compounds at CCR3 to be calculated.

### EXAMPLE 35

#### Guinea-pig isolated trachea

(See for example, Harrison, R.W.S., Carswell, H. & Young, J.M. (1984) *European J. Pharmacol.*, 106, 405-409.)

Male albino Dunkin-Hartley guinea-pigs (250g) were killed by cervical dislocation and the whole trachea removed. After clearing the adherent connective tissue, the trachea was cut into six ring segments each three cartilage bands wide and then suspended in 20ml organ baths containing Krebs-Henseleit solution of the following composition (mM): NaCl 117.6, NaH<sub>2</sub>PO<sub>4</sub> 0.9, NaHCO<sub>3</sub> 25.0, MgSO<sub>4</sub> 1.2, KCl 5.4, CaCl<sub>2</sub> 2.6 and glucose 11.1. The buffer was maintained at 37°C and gassed with 5% CO<sub>2</sub> in oxygen. Indomethacin (2.8µM) was added to the Krebs solution to prevent development of smooth muscle tone due to the synthesis of cyclo-

oxygenase products. The tracheal rings were suspended between two parallel tungsten wire hooks, one attached to an Ormed beam isometric force transducer and the other to a stationary support in the organ bath. Changes in isometric force were recorded on 2-channel Sekonic flat bed chart recorders.

#### 5 Experimental protocols

At the beginning of each experiment a force of 1g was applied to the tissues and this was reinstated over a 60 minute equilibration period until a steady resting tone was achieved. Subsequently, a cumulative histamine concentration effect ( $E/[A]$ ) curve was constructed at 0.5  $\log_{10}$  unit increments, in each tissue. The tissues were then washed and approximately 30  
10 minutes later, test compound or vehicle (20% DMSO) was added. Following an incubation period of 60 minutes a second  $E/[A]$  curve was performed to histamine.

Contraction responses were recorded as a percentage of the first curve maximum.

#### Data analysis

Experimental  $E/[A]$  curve data were analysed for the purposes of estimating the  
15 potencies ( $p[A_{50}]$  values) of histamine in the absence and presence of the test compound. Affinity ( $pA_2$ ) values of test compounds were subsequently calculated using the following equation:

$$\log(r-1) = \log[B] + pA_2$$

where  $r = [A]_{50}$  in presence of test compound/ $[A]_{50}$  in absence of antagonist and  $[B]$  is the  
20 concentration of test compound. Compounds of the Examples were found to be H1 antagonists.

#### EXAMPLE 36

Histamine H1 receptor binding activity of compounds of the invention was assessed by competition displacement of 1nM  $[3H]$ -pyrilamine (Amersham, Bucks,  
25 Product code TRK 608, specific activity 30Ci/mmol) to 2 $\mu$ g membranes prepared from recombinant CHO-K1 cells expressing the human H1 receptor (Euroscreen SA, Brussels, Belgium, product code ES-390-M) in assay buffer (50mM Tris pH 7.4 containing 2mM  $MgCl_2$ , 250mM sucrose and 100mM NaCl) for 1 hour at room temperature.

The following compounds of the invention gave inhibition of  $[3H]$  pyrilimine  
30 binding:


7/11/04

Example	H1 pKi /[1328_S]
17	8.3
18	7.8
19	7.8
20	7.9
21	7.8
22	8.3
23	7.4
24	7.5
25	8.0
26	7.9
27	7.9
29	7.9

7/11/04

CLAIMS

1. A compound of formula (I):



5 wherein:

one of A, B, D, E and G is  $CXYCO_2R^5$ , another is CH or N and the others are  $CR^2$ ,  $CR^3$  and  $CR^4$ ;

Q is hydrogen or hydroxy;

W is  $CH_2$ , O, NH or  $N(C_{1-4} \text{ alkyl})$ ;

10 X is O or a bond;

Y is  $CR^{10}R^{11}$ ,  $CR^{10}R^{11}CR^{12}R^{13}$ ,  $CR^{10}R^{11}CR^{12}R^{13}CR^{14}R^{15}$ ;

$R^1$  is phenyl optionally substituted by halogen, cyano,  $C_{1-4}$  alkyl,  $C_{1-4}$  haloalkyl,  $C_{1-4}$  alkoxy or  $C_{1-4}$  haloalkoxy;

15  $R^2$ ,  $R^3$  and  $R^4$  are, independently, hydrogen, halogen, cyano, nitro, hydroxy,  $NR^6R^7$ ,  $C_{1-6}$  alkyl (optionally substituted with halogen),  $C_{1-6}$  alkoxy (optionally substituted with halogen),  $S(O)_p(C_{1-6} \text{ alkyl})$ ,  $S(O)_qCF_3$  or  $S(O)_2NR^8R^9$ ;

$R^5$  is hydrogen,  $C_{1-6}$  alkyl or benzyl;

p and q are, independently, 0, 1 or 2;

20  $R^6$ ,  $R^7$ ,  $R^8$  and  $R^9$  are, independently, hydrogen,  $C_{1-6}$  alkyl (optionally substituted by halogen, hydroxy or  $C_{3-6}$  cycloalkyl),  $CH_2(C_{2-5} \text{ alkenyl})$ , phenyl (itself optionally substituted by halogen, hydroxy, nitro,  $NH_2$ ,  $NH(C_{1-4} \text{ alkyl})$ ,  $N(C_{1-4} \text{ alkyl})_2$  (and these alkyl groups may join to form a ring as described for  $R^6$  and  $R^7$  below),  $S(O)_2(C_{1-4} \text{ alkyl})$ ,  $S(O)_2NH_2$ ,  $S(O)_2NH(C_{1-4} \text{ alkyl})$ ,  $S(O)_2N(C_{1-4} \text{ alkyl})_2$  (and these alkyl groups may join to form a ring as described for  $R^6$  and  $R^7$  below), cyano,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy,  $C(O)NH_2$ ,  $C(O)NH(C_{1-4} \text{ alkyl})$ ,  $C(O)N(C_{1-4} \text{ alkyl})_2$  (and these alkyl groups may join to form a ring as described for  $R^6$  and  $R^7$  below),  $CO_2H$ ,  $CO_2(C_{1-4} \text{ alkyl})$ ,  $NHC(O)(C_{1-4} \text{ alkyl})$ ,  $NHS(O)_2(C_{1-4} \text{ alkyl})$ ,  $C(O)(C_{1-4} \text{ alkyl})$ ,  $CF_3$  or  $OCF_3$ ) or heterocyclyl (itself optionally substituted by halogen, hydroxy, nitro,  $NH_2$ ,  $NH(C_{1-4} \text{ alkyl})$ ,  $N(C_{1-4} \text{ alkyl})_2$  (and these alkyl groups may join to form a ring

as described for  $R^6$  and  $R^7$  below),  $S(O)_2(C_{1-4} \text{ alkyl})$ ,  $S(O)_2NH_2$ ,  $S(O)_2NH(C_{1-4} \text{ alkyl})$ ,  $S(O)_2N(C_{1-4} \text{ alkyl})_2$  (and these alkyl groups may join to form a ring as described for  $R^6$  and  $R^7$  below), cyano,  $C_{1-4} \text{ alkyl}$ ,  $C_{1-4} \text{ alkoxy}$ ,  $C(O)NH_2$ ,  $C(O)NH(C_{1-4} \text{ alkyl})$ ,  $C(O)N(C_{1-4} \text{ alkyl})_2$  (and these alkyl groups may join to form a ring as described for  $R^6$  and  $R^7$  below),  $CO_2H$ ,  $CO_2(C_{1-4} \text{ alkyl})$ ,  $NHC(O)(C_{1-4} \text{ alkyl})$ ,  $NHS(O)_2(C_{1-4} \text{ alkyl})$ ,  $C(O)(C_{1-4} \text{ alkyl})$ ,  $CF_3$  or  $OCF_3$ ); alternatively  $NR^6R^7$  or  $NR^8R^9$  may, independently, form a 4-7 membered heterocyclic ring, azetidine, pyrrolidine, piperidine, azepine, morpholine or piperazine, the latter optionally substituted by  $C_{1-4} \text{ alkyl}$  on the distal nitrogen;  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$  and  $R^{15}$  are, independently, hydrogen or  $C_{1-4} \text{ alkyl}$ ; or  $R^{10}$  and  $R^{11}$ , and the carbon to which they are both attached, together form a  $C_{3-6}$  cycloalkyl ring, for  $C_{4-6}$  cycloalkyl rings said ring optionally having a ring carbon, but not the ring carbon to which  $R^{10}$  and  $R^{11}$  are both attached, replaced by O,  $S(O)$  or  $S(O)_2$ ; or an N-oxide thereof; or a pharmaceutically acceptable salt thereof; or a solvate thereof.


2. A process for preparing a compound of formula (I) as claimed in claim 1.
3. A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1, and a pharmaceutically acceptable adjuvant, diluent or carrier.
4. A compound of the formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1, for use in therapy.
5. A compound of formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1, in the manufacture of a medicament for use in therapy.
6. A method of treating a chemokine mediated disease state in a mammal suffering from, or at risk of, said disease, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of





ABSTRACT  
CHEMICAL COMPOUNDS

The present invention provides a compound of a formula (I):



5

wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.